Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy. (ASH 2025) - Dec 5, 2025 - "Such effect has been retrospectively observed also in the setting of haploidentical alloHCT (Haplo) using post-transplant cyclophosphamide (PTCy), a very-high risk landscape for CMVr and disease...We included adult patients (> 18y.o), with oncohematological diseases, receiving a first Haplo, using myeloablativemor reduced intensity conditioning (RIC) based on thiotepa/fludarabine/busulphan (TBF), peripheral blood stem cells as graft source, a GVHD prophylaxis based on PTCy... LTV is associated to a significant reduction in CMVr also in a high-risk population (Haplo with PTCy) without observing significant differences in terms of NRM. For those patients experiencing CMVr, the previous use of LTV was associated to a delayed reactivation and absence of CMV disease or death. Larger cohort of patients will be necessary to confirm these results"
Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Nephrology • Non-Hodgkin's Lymphoma
|
|
Felipe Peña-Muñoz; Fernando Molina; Marta Peña; Julia Ribes-Amoros; Anna Torrent; Maria Huguet; Merce Aren Jubany; Silvana Novelli; Cristina Fernandez; Raquel Lopez; Lidia Hurtado; Montserrat Arnan; Eva Gonzalez Barca; Carlota Gudiol; Julia Laporte; Anna Sureda Balarí; Alberto Mussetti
|